Search details
1.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37789669
2.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37983642
3.
Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
Oncology
; 101(3): 193-202, 2023.
Article
in English
| MEDLINE | ID: mdl-36649691
4.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Article
in English
| MEDLINE | ID: mdl-37307798
5.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37306040
6.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37020416
7.
Metabolic syndrome is linked to the incidence of pancreatic cancer.
EClinicalMedicine
; 67: 102353, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38169901
8.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Aliment Pharmacol Ther
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38716823
9.
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Cancer Rep (Hoboken)
; 7(4): e2042, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38577725
10.
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.
Cancers (Basel)
; 15(6)2023 Mar 16.
Article
in English
| MEDLINE | ID: mdl-36980684
11.
Relationship between Being Overweight and Clinical Outcomes of Ablation Therapy for Hepatocellular Carcinoma under Ultrasound Guidance: A Retrospective Analysis.
Cancers (Basel)
; 15(4)2023 Feb 17.
Article
in English
| MEDLINE | ID: mdl-36831630
12.
Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.
Cancer Med
; 12(17): 17849-17855, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37563961
13.
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
J Gastroenterol
; 58(11): 1134-1143, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37528255
14.
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Cancers (Basel)
; 15(17)2023 Aug 31.
Article
in English
| MEDLINE | ID: mdl-37686624
15.
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Cancer Med
; 12(24): 21680-21693, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37987139
16.
Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
J Gastroenterol Hepatol
; 27(1): 69-75, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-21649727
17.
Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model.
J Hepatol
; 51(1): 168-75, 2009 Jul.
Article
in English
| MEDLINE | ID: mdl-19446916
18.
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis.
Hepatology
; 47(6): 2010-25, 2008 Jun.
Article
in English
| MEDLINE | ID: mdl-18506889
19.
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Liver Int
; 29(7): 988-96, 2009 Aug.
Article
in English
| MEDLINE | ID: mdl-19386026
20.
[A case of advanced hepatocellular carcinoma effectively treated with 5-fluorouracil and high-concentration cisplatin suspended in lipiodol by short-term hepatic arterial infusion chemotherapy].
Gan To Kagaku Ryoho
; 36(7): 1179-81, 2009 Jul.
Article
in Japanese
| MEDLINE | ID: mdl-19620813